Phase-III of Biomedical Research Career Programme Launched

New Delhi, October 9 (IANS) – The Indian government has officially launched Phase-III of the Biomedical Research Career Programme (BRCP) aimed at addressing regional imbalances and amplifying the presence of women scientists in the nation’s research landscape.

Program Overview

Approved by the Union Cabinet earlier this month, Phase-III is set to be implemented from 2025 to 2031, with an additional service phase extending until 2037. This initiative is backed by a robust financial framework, featuring a total budget of Rs 1,500 crore. The Department of Biotechnology, under the Ministry of Science and Technology, will contribute Rs 1,000 crore, while the Wellcome Trust from the UK will provide Rs 500 crore.

Aims and Objectives

The primary goals of BRCP Phase-III include:

• Bridging regional disparities in biomedical research.
• Encouraging inclusivity, with a specific focus on promoting women scientists.
• Providing fellowships and collaborative grants to researchers at various career stages.
• Fostering ethical research that addresses significant public health challenges in India.

Impact and Expectations

The program is anticipated to train over 2,000 students and post-doctoral fellows, lead to high-impact academic publications, and generate patentable innovations. It aims to elevate 25-30% of collaborative projects to Technology Readiness Level (TRL-4).

Additionally, the initiative intends to enhance opportunities for women scientists, providing a significant increase in support by 10-15%, thus fortifying inclusivity in India’s research ecosystem.

Alignment with National Goals

According to an official statement, “Phase-III is expected to set new benchmarks for biomedical excellence in India.” This initiative aligns well with India’s national vision for Viksit Bharat 2047, aspiring to position the nation as a leading global hub for innovation and translational research in the biomedical field.

Previous Contributions to Healthcare

Biomedical research in India has notably contributed to advancements such as low-cost diagnostics—including CRISPR-based kits and rapid tests for dengue—as well as the development of indigenous vaccines for diseases such as pneumonia, measles-rubella, and COVID-19. These efforts are pivotal in making healthcare more affordable and equitable, contributing to India’s self-reliance and leadership in biomedical innovation.